Research Article
The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
Table 3
Five-year Kaplan-Meier overall survival by race.
| | | Total | White | Black | Hispanic | Asian | Log-rank value |
| | Overall | 73.4% (±0.9) | 73.8% (±1.2) | 66.3% (±2.6) | 74.0% (±3.8) | 85.3% (±3.3) | < 0.001 | | Age | | | | | | < 0.001 | | 65 years | 83.2% (±1.1) | 84.8% (±1.2) | 74.3% (±3.0) | 80.9% (±4.4) | 88.6% (±4.0) | < 0.001 | | 65 years | 64.5% (±1.3) | 65.1% (±1.4) | 53.1% (±4.4) | 60.7% (±6.5) | 81.6% (±5.3) | = 0.011 | | Year of diagnosis | | | | | | = 0.018 | | 1988–1993 | 68.9% (±2.2) | 69.1% (±2.4) | 60.4% (±7.1) | 64.7% (±11.6) | 80.8% (±7.7) | = 0.549 | | 1994–1999 | 72.0% (±1.7) | 74.5% (±1.9) | 55.6% (±5.5) | 57.6% (±8.6) | 87.5% (±5.8) | < 0.001 | | 2000–2005 | 75.2% (±1.1) | 74.8% (±1.3) | 71.8% (±3.1) | 82.4% (±4.1) | 86.2% (±4.5) | = 0.031 | | Marital status | | | | | | < 0.001 | | Single | 68.7% (±2.6) | 69.8% (±3.1) | 58.5% (±5.7) | 76.6% (±8.4) | 85.7% (±13.2) | = 0.144 | | Married | 77.5% (±1.0) | 77.6% (±1.1) | 73.7% (±3.3) | 72.8% (±4.7) | 87.4% (±3.4) | = 0.037 | | Separated | 46.0% (±10.2) | 41.7% (±14.2) | 44.4% (±16.6) | 50.0% (±35.4) | — | = 0.665 | | Divorced | 68.9% (±3.4) | 68.3% (±4.0) | 72.7% (±7.8) | 77.8% (±13.9) | 33.3% (±27.2) | = 0.528 | | Widowed | 51.9% (±3.5) | 53.1% (±3.9) | 33.3% (±9.6) | 71.4% (±17.1) | 71.4% (±17.1) | = 0.174 | | Unknown | 66.7% (±4.9) | 66.7% (±5.6) | 65.7% (±12.5) | 33.3% (±27.2) | 100.0% (±0.0) | = 0.694 | | Histology | | | | | | < 0.001 | | In situ | 91.3% (±1.6) | 90.0% (±2.0) | 94.6% (±3.7) | 94.1% (±5.7) | 100.0% (±0.0) | = 0.543 | | Ductal | 70.6% (±1.0) | 71.2% (±1.1) | 62.1% (±3.0) | 69.2% (±4.5) | 83.5% (±3.9) | < 0.001 | | Papillary | 75.6% (±6.4) | 75.0% (±7.7) | 88.9% (±10.5) | 50.0% (±35.4) | 50.0% (±35.4) | = 0.457 | | Mucinous | 81.1% (±5.4) | 87.5% (±5.8) | 62.5% (±12.1) | 100.0% (±0.0) | — | = 0.034 | | Medullary | 100.0% (±0.0) | 100.0% (±0.0) | — | — | 100.0% (±0.0) | — | | Lobular | 75.1% (±5.0) | 75.2% (±5.6) | 57.1% (±18.7) | 50.0% (±25.0) | 80.0% (±17.9) | = 0.352 | | ER/PR status | | | | | | = 0.057 | | ER−/PR− | 71.8% (±4.0) | 71.8% (±4.9) | 70.8% (±9.3) | 57.1% (±18.7) | 87.5% (±11.7) | = 0.175 | | ER+/PR− | 65.5% (±3.0) | 67.8% (±3.4) | 57.7% (±8.1) | 55.6% (±16.6) | 57.1% (±18.7) | = 0.487 | | ER+/PR+ | 73.3% (±1.2) | 73.2% (±1.3) | 66.1% (±3.9) | 74.3% (±5.2) | 89.6% (±3.7) | = 0.006 | | Unknown | 76.1% (±1.5) | 76.9% (±1.7) | 68.4% (±4.1) | 79.4% (±5.8) | 81.9% (±6.7) | = 0.045 | | Treatment | | | | | | < 0.001 | | None | 45.9% (±5.1) | 50.0% (±6.4) | 33.3% (±10.3) | 60.0% (±21.9) | 35.7% (±19.8) | = 0.329 | | Primary RT | 31.8% (±7.0) | 30.3% (±8.0) | 42.9% (±18.7) | 25.0% (±21.7) | — | = 0.904 | | Partial mast. | 80.0% (±2.6) | 78.1% (±3.1) | 78.8% (±7.1) | 80.8% (±12.2) | 100.0% (±0.0) | = 0.271 | | Nipple-sparing mast. | 75.0% (±10.8) | 91.7% (±8.0) | 25.0% (±21.7) | — | — | = 0.004 | | Simple mast. | 77.1% (±1.9) | 75.5% (±2.2) | 82.6% (±5.3) | 88.5% (±6.3) | 79.6% (±9.1) | = 0.294 | | Modified rad. mast. | 74.0% (±1.0) | 74.9% (±1.2) | 64.9% (±3.3) | 71.6% (±4.8) | 87.2% (±4.0) | = 0.002 | | Rad. mast. | 59.3% (±9.5) | 52.6% (±11.5) | 71.4% (±17.1) | — | — | = 0.321 | | Surgery, NOS | 80.0% (±10.3) | 75.0% (±12.5) | 100.0% (±0.0) | — | 0.0% (±0.0) | = 0.727 | | LNDX | | | | | | < 0.001 | | No | 61.0% (±2.3) | 60.9% (±2.6) | 58.6% (±5.9) | 66.2% (±9.8) | 65.3% (±10.7) | = 0.592 | | Yes | 76.0% (±0.9) | 76.3% (±1.0) | 68.3% (±2.8) | 75.7% (±4.1) | 89.6% (±3.1) | < 0.001 | | Adjuvant RT | | | | | | = 0.738 | | No | 73.9% (±1.0) | 74.3% (±1.1) | 67.5% (±2.9) | 75.6% (±4.2) | 82.7% (±3.9) | = 0.033 | | Yes | 74.7% (±1.8) | 75.0% (±2.1) | 64.4% (±5.7) | 67.9% (±8.8) | 95.7% (±4.3) | = 0.003 | | Nodal metastases | | | | | | < 0.001 | | No | 77.0% (±1.0) | 77.1% (±1.1) | 74.1% (±3.0) | 76.3% (±4.5) | 85.3% (±4.1) | = 0.101 | | Yes | 66.8% (±1.5) | 67.7% (±1.7) | 53.3% (±4.4) | 69.6% (±6.8) | 85.4% (±5.5) | < 0.001 | | Stage | | | | | | < 0.001 | | 0 | 91.3% (±1.6) | 90.0% (±2.0) | 94.6% (±3.7) | 94.1% (±5.7) | 100.0% (±0.0) | = 0.543 | | I | 83.8% (±1.3) | 83.5% (±1.5) | 85.3% (±3.8) | 76.9% (±6.7) | 92.3% (±4.3) | = 0.246 | | II | 74.2% (±1.4) | 74.2% (±1.6) | 67.0% (±4.3) | 79.5% (±6.1) | 88.8% (±4.7) | = 0.005 | | III | 55.5% (±2.4) | 57.8% (±2.8) | 37.0% (±6.0) | 64.5% (±9.0) | 61.5% (±13.5) | = 0.005 | | IV | 19.4% (±3.4) | 17.5% (±3.9) | 30.8% (±9.1) | 14.3% (±13.2) | — | = 0.421 | | Grade | | | | | | < 0.001 | | 1 | 84.7% (±2.1) | 85.1% (±2.4) | 76.5% (±7.3) | 91.7% (±8.0) | 92.9% (±6.9) | = 0.390 | | 2 | 76.5% (±1.3) | 76.9% (±1.4) | 67.8% (±4.1) | 74.2% (±6.0) | 94.1% (±3.3) | = 0.005 | | 3 | 65.2% (±1.6) | 65.7% (±1.8) | 57.4% (±4.8) | 65.1% (±7.3) | 77.1% (±7.1) | = 0.014 | | Unknown | 73.9% (±2.1) | 73.9% (±2.4) | 72.5% (±5.4) | 72.5% (±8.9) | 70.6% (±11.1) | = 0.899 |
|
|
Mast = mastectomy; RT = radiotherapy; LNDX = lymph node dissection; ER = estrogen receptor; PR = progesterone receptor.
|
